JP2009544711A5 - - Google Patents

Download PDF

Info

Publication number
JP2009544711A5
JP2009544711A5 JP2009521823A JP2009521823A JP2009544711A5 JP 2009544711 A5 JP2009544711 A5 JP 2009544711A5 JP 2009521823 A JP2009521823 A JP 2009521823A JP 2009521823 A JP2009521823 A JP 2009521823A JP 2009544711 A5 JP2009544711 A5 JP 2009544711A5
Authority
JP
Japan
Prior art keywords
cells
composition
cell
polynucleotide
lethal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009544711A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/016747 external-priority patent/WO2008073154A2/en
Publication of JP2009544711A publication Critical patent/JP2009544711A/ja
Publication of JP2009544711A5 publication Critical patent/JP2009544711A5/ja
Pending legal-status Critical Current

Links

JP2009521823A 2006-07-26 2007-07-26 疾病の治療方法及び疾病治療用組成物 Pending JP2009544711A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82038106P 2006-07-26 2006-07-26
US88909507P 2007-02-09 2007-02-09
PCT/US2007/016747 WO2008073154A2 (en) 2006-07-26 2007-07-26 Methods and compositions for treating disease

Publications (2)

Publication Number Publication Date
JP2009544711A JP2009544711A (ja) 2009-12-17
JP2009544711A5 true JP2009544711A5 (enExample) 2010-09-09

Family

ID=39512236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521823A Pending JP2009544711A (ja) 2006-07-26 2007-07-26 疾病の治療方法及び疾病治療用組成物

Country Status (16)

Country Link
US (3) US20100003226A1 (enExample)
EP (1) EP2043662B1 (enExample)
JP (1) JP2009544711A (enExample)
KR (1) KR20090035011A (enExample)
AU (1) AU2007332980A1 (enExample)
CA (1) CA2658836C (enExample)
DK (1) DK2043662T3 (enExample)
ES (1) ES2553332T3 (enExample)
HU (1) HUE027142T2 (enExample)
IL (1) IL196638A (enExample)
MX (1) MX2009000966A (enExample)
NZ (1) NZ575075A (enExample)
PL (1) PL2043662T3 (enExample)
PT (1) PT2043662E (enExample)
RU (1) RU2468820C2 (enExample)
WO (1) WO2008073154A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109944A1 (en) * 2012-01-18 2013-07-25 The Trustees Of The University Of Pennsylvania Methods for assessing risk for cancer using biomarkers
EA029382B1 (ru) 2012-05-09 2018-03-30 Кантекс Фармасьютикалз, Инк. Лечение миелосупрессии
EP3258941A4 (en) 2015-02-17 2018-09-26 Cantex Pharmaceuticals, Inc. Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction
WO2016133907A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
KR20180069081A (ko) 2015-11-11 2018-06-22 인트렉손 코포레이션 심장 이상 및 기타 병리 이상의 치료를 위한 복수의 생물학적으로 활성화된 폴리펩티드를 단일 벡터로부터 발현하기 위한 조성물 및 방법
JP7051060B2 (ja) * 2017-05-09 2022-04-11 学校法人慶應義塾 脳腫瘍治療用細胞製剤

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
EP1188448A3 (en) * 1994-03-15 2002-04-17 Prizm Pharmaceuticals, Inc. Heparin-binding growth factors for gene therapy and anterior eye disorders
WO1996036362A1 (en) * 1995-05-16 1996-11-21 Prizm Pharmaceuticals, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
WO1997049434A2 (en) * 1996-06-24 1997-12-31 Prizm Pharmaceuticals, Inc. Heparinized medical devices containing heparin-binding growth factor conjugates
AU755251B2 (en) * 1998-02-19 2002-12-05 St. Jude Children's Research Hospital Compositions and methods for sensitizing and inhibiting growth of human tumor cells
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
DE60043889D1 (en) * 1999-06-07 2010-04-08 Tet Systems Holding Gmbh & Co Tet repressor basierte transkriptionale regulatorische proteine
JP5031967B2 (ja) 2000-03-22 2012-09-26 イントレキソン コーポレーション 新規エクジソン受容体ベースの誘導性遺伝子発現系
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
DK1311661T3 (da) * 2000-08-14 2012-11-26 Us Gov Health & Human Serv Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
CA2435503C (en) * 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
ES2422303T3 (es) 2001-02-20 2013-09-10 Intrexon Corp Receptores mutantes por sustitución novedosos y su uso en un sistema de expresión génica inducible basado en receptores nucleares
CA2438119C (en) 2001-02-20 2014-12-16 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
AU2002248500B2 (en) 2001-02-20 2007-12-13 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ES2385598T3 (es) 2001-02-20 2012-07-27 Intrexon Corporation Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
US6828102B2 (en) * 2001-11-20 2004-12-07 Albany Medical College Plasmids and methods for monitoring endonuclease digestion efficiency
EP1327688A1 (en) * 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
EP1529110B1 (en) * 2002-08-01 2011-10-05 Evolva Ltd. Methods of mixing large numbers of heterologous genes
US7785871B2 (en) 2002-10-09 2010-08-31 Intrexon Corporation DNA cloning vector plasmids and methods for their use
EP1631319A4 (en) * 2003-05-30 2007-10-31 Cleveland Clinic Foundation IN VIVO PRODUCTION OF A CLOSTRIDIUM NEUROTOXIN LIGHT CHAIN PEPTIDE
CA2436196A1 (en) * 2003-07-25 2005-01-25 Oncolytics Biotech Inc. Oncolytic virus for purging cellular compositions of cells of lymphoid malignancies
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
AU2005248371B2 (en) 2004-05-18 2011-12-15 Intrexon Corporation Methods for dynamic vector assembly of DNA cloning vector plasmids

Similar Documents

Publication Publication Date Title
US11535871B2 (en) Optimized gene editing utilizing a recombinant endonuclease system
JP2009544711A5 (enExample)
CA3178670A1 (en) Programmable nucleases and methods of use
CN109475109A (zh) 用于使用多个引导rna来破坏免疫耐受性的方法
JP6755801B2 (ja) 治療的な使用のための、核酸送達のための治療用ファージおよび方法
KR20180120752A (ko) 베타 이상헤모글로빈증의 치료를 위한 crispr/cas-관련 방법 및 조성물
DE69839403T2 (de) Adenovirale vektoren und eine methode zur reduktion von homologer rekombination
KR20180031671A (ko) 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
Hülter et al. Intracellular competitions reveal determinants of plasmid evolutionary success
KR20190037145A (ko) 유전자 발현 조절을 위한 인위적인 게놈 조작
CN105316322B (zh) 一种sgRNA碱基错配靶位点文库及其应用
Cai et al. Development of CRISPR-mediated systems in the study of Duchenne muscular dystrophy
CN117120602A (zh) 分裂的cas12系统及其使用方法
Frimodt-Møller et al. Control regions for chromosome replication are conserved with respect to sequence and location among Escherichia coli strains
Sykes et al. Recent advances in genetic tools for Acinetobacter baumannii
RU2009103208A (ru) Способы и композиции для лечения заболевания
CN111712566A (zh) 用于筛选靶基因变体的方法
EP4127181A1 (en) Genome engineering using crispr rna-guided integrases
CN116024670A (zh) 一种柑橘溃疡病诱导转录因子酵母文库、构建方法及其应用
US6998263B2 (en) Methods of preparing and using a viral vector library
US20220364122A1 (en) Bacterial platform for delivery of gene-editing systems to eukaryotic cells
CN115299406B (zh) 动物模型的构建方法及消融脂肪细胞的方法
CN116284444A (zh) 一种基于ShCAST系统的定点基因插入工具及应用
JPH05505529A (ja) 新規な薬物および試薬の同定
CN115487315A (zh) 治疗亨廷顿病的药物